Precision Medicine Advisors Blog posts
Whether it’s a physician trying to decide which laboratory’s genetic test to order, or a regulator assessing the safety and efficacy of a test, or a payer needing to make a coverage determination, all would benefit from having a coherent framework for evaluating genetic tests.
As genomic testing moves into the mainstream, there is an increased risk of lawsuits against healthcare providers. Medical malpractice claims could arise from the use, failure to use, or misuse of genomic information by healthcare providers.
Diabetes is a chronic condition characterized by elevated levels of blood glucose and the inability to properly process food for use as energy. Diabetes is a heterogeneous disease, with several different types and a mostly complex genetic etiology.
This month, the US Food and Drug Administration (FDA) sent genetic testing company Inova Genomics a warning letter because they were selling a suite of pharmacogenomic (PGx) testing products, marketed under the name MediMap, without obtaining prior FDA authorization to do so.
Patients with breast cancer as well as healthy at-risk individuals can benefit from genetic testing to determine whether their cancer is due to an inherited pathogenic variant in a cancer-causing gene. But the results of those tests are not always clear cut.
The genetic basis of common diseases like diabetes, cancer, heart disease, asthma and Alzheimer’s disease is complex. The genetic underpinning of most cases of common diseases is not monogenic, but rather, polygenic. In other words, there are genetic variants of dozens of different genes, each with a tiny effect on disease risk.
23andMe has recently received FDA clearance to offer pharmacogenetic testing to its customers. The test covers a total of 33 variants from eight pharmacogenes. How does the 23andMe product stack up against commercially available PGx tests? Is the 23andMe product any good?
The early adopters of precision medicine: getting the right genetic tests into the right hands